Is ivermectin–Azithromycin combination the next step for COVID-19?
Different experimental and approved drugs were tested for coronavirus infection disease (COVID-19) to detect effective one that attenuates or prevents the pathogenesis of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). Repurposing of old approved drugs with the potential arrhythmo...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
| Series: | Biomedical and Biotechnology Research Journal |
| Subjects: | |
| Online Access: | http://www.bmbtrj.org/article.asp?issn=2588-9834;year=2020;volume=4;issue=5;spage=101;epage=103;aulast=Al-Kuraishy |
| _version_ | 1819014688829079552 |
|---|---|
| author | Hayder Mutter Al-Kuraishy Nawar Raad Hussien Marwa Salih Al-Naimi Ali Kadhem Al-Buhadily Ali Ismail Al-Gareeb Claire Lungnier |
| author_facet | Hayder Mutter Al-Kuraishy Nawar Raad Hussien Marwa Salih Al-Naimi Ali Kadhem Al-Buhadily Ali Ismail Al-Gareeb Claire Lungnier |
| author_sort | Hayder Mutter Al-Kuraishy |
| collection | DOAJ |
| description | Different experimental and approved drugs were tested for coronavirus infection disease (COVID-19) to detect effective one that attenuates or prevents the pathogenesis of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). Repurposing of old approved drugs with the potential arrhythmogenic effect such as chloroquine in COVID-19 may increase the risk of sudden cardiac death due to torsadogenic potential. The Food and Drug Administration approved the drugs, such as ivermectin, which can kill SARS-CoV-2 within 48 h. Azithromycin augments the antiviral activity of chloroquine in COVID-19 with a high risk of morbidity and mortality through torsadogenic potential. There were no obvious interactions between ivermectin and azithromycin and without risk of torsadogenic effect despite the prolongation of QT by azithromycin. Therefore, azithromycin–ivermectin is regarded as an effectual combo for COVID-19 in elderly patients with underlying cardiac abnormalities. |
| first_indexed | 2024-12-21T02:19:49Z |
| format | Article |
| id | doaj.art-df570638a9d848d6b0e6438d6ecc9b37 |
| institution | Directory Open Access Journal |
| issn | 2588-9834 2588-9842 |
| language | English |
| last_indexed | 2024-12-21T02:19:49Z |
| publishDate | 2020-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Biomedical and Biotechnology Research Journal |
| spelling | doaj.art-df570638a9d848d6b0e6438d6ecc9b372022-12-21T19:19:10ZengWolters Kluwer Medknow PublicationsBiomedical and Biotechnology Research Journal2588-98342588-98422020-01-014510110310.4103/bbrj.bbrj_109_20Is ivermectin–Azithromycin combination the next step for COVID-19?Hayder Mutter Al-KuraishyNawar Raad HussienMarwa Salih Al-NaimiAli Kadhem Al-BuhadilyAli Ismail Al-GareebClaire LungnierDifferent experimental and approved drugs were tested for coronavirus infection disease (COVID-19) to detect effective one that attenuates or prevents the pathogenesis of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). Repurposing of old approved drugs with the potential arrhythmogenic effect such as chloroquine in COVID-19 may increase the risk of sudden cardiac death due to torsadogenic potential. The Food and Drug Administration approved the drugs, such as ivermectin, which can kill SARS-CoV-2 within 48 h. Azithromycin augments the antiviral activity of chloroquine in COVID-19 with a high risk of morbidity and mortality through torsadogenic potential. There were no obvious interactions between ivermectin and azithromycin and without risk of torsadogenic effect despite the prolongation of QT by azithromycin. Therefore, azithromycin–ivermectin is regarded as an effectual combo for COVID-19 in elderly patients with underlying cardiac abnormalities.http://www.bmbtrj.org/article.asp?issn=2588-9834;year=2020;volume=4;issue=5;spage=101;epage=103;aulast=Al-Kuraishyazithromycinchloroquinecovid-19ivermectinsevere acute respiratory syndrome coronavirus type 2torsadogenic potential |
| spellingShingle | Hayder Mutter Al-Kuraishy Nawar Raad Hussien Marwa Salih Al-Naimi Ali Kadhem Al-Buhadily Ali Ismail Al-Gareeb Claire Lungnier Is ivermectin–Azithromycin combination the next step for COVID-19? Biomedical and Biotechnology Research Journal azithromycin chloroquine covid-19 ivermectin severe acute respiratory syndrome coronavirus type 2 torsadogenic potential |
| title | Is ivermectin–Azithromycin combination the next step for COVID-19? |
| title_full | Is ivermectin–Azithromycin combination the next step for COVID-19? |
| title_fullStr | Is ivermectin–Azithromycin combination the next step for COVID-19? |
| title_full_unstemmed | Is ivermectin–Azithromycin combination the next step for COVID-19? |
| title_short | Is ivermectin–Azithromycin combination the next step for COVID-19? |
| title_sort | is ivermectin azithromycin combination the next step for covid 19 |
| topic | azithromycin chloroquine covid-19 ivermectin severe acute respiratory syndrome coronavirus type 2 torsadogenic potential |
| url | http://www.bmbtrj.org/article.asp?issn=2588-9834;year=2020;volume=4;issue=5;spage=101;epage=103;aulast=Al-Kuraishy |
| work_keys_str_mv | AT haydermutteralkuraishy isivermectinazithromycincombinationthenextstepforcovid19 AT nawarraadhussien isivermectinazithromycincombinationthenextstepforcovid19 AT marwasalihalnaimi isivermectinazithromycincombinationthenextstepforcovid19 AT alikadhemalbuhadily isivermectinazithromycincombinationthenextstepforcovid19 AT aliismailalgareeb isivermectinazithromycincombinationthenextstepforcovid19 AT clairelungnier isivermectinazithromycincombinationthenextstepforcovid19 |